After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...